SCHEMBL7657453

SCHEMBL7657453

Cc1cc2c(s1)Oc1ccc([N+](=O)[O-])cc1NC2=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.51
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
POLB P06746 4/20 0.51
ALDH1A1 P00352 3/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
CAPN9 O14815 1/20 0.44
CASP3 P42574 1/20 0.44
CYP3A4 P08684 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
TDP2 O95551 1/20 0.39
GSK3B P49841 4/20 0.38
EGFR P00533 1/20 0.38
CHEK1 O14757 1/20 0.38
PDPK1 O15530 1/20 0.38
ROCK2 O75116 1/20 0.38
RPS6KA5 O75582 1/20 0.38
MAP4K4 O95819 1/20 0.38
CHEK2 O96017 1/20 0.38
CDK1 P06493 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7665527 0.90 MAPT (0.54) MAPTMEN1KMT2APOLBALDH1A1
SCHEMBL7659353 0.82 MMP12 (0.47) MAPTPOLBALDH1A1TDP1CDK5
SCHEMBL7660369 0.80 TGM2 (0.37) MEN1KMT2A
SCHEMBL7664938 0.80 CES1 (0.42) MAPTPOLBCHEK1LMNA
SCHEMBL7658523 0.78 MAPT (0.47) MAPTMEN1KMT2APOLBALDH1A1
SCHEMBL13437129 0.76 MAPT (0.57) MAPTMEN1KMT2APOLBALDH1A1
Dimethylamine SCHEMBL7666545 0.74 MAPT (0.44) MAPTMEN1KMT2APOLBALDH1A1
SCHEMBL7658309 0.74 ALDH1A1 (0.46) MAPTMEN1KMT2APOLBALDH1A1
SCHEMBL7661672 0.72 CES1 (0.42) MAPTALDH1A1CHEK1RPS6KA3RAB9A
SCHEMBL7666555 0.72 KMT2A (0.37) MAPTMEN1KMT2AALDH1A1CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT MAPT 15/4885MEN1 1756/4885KMT2A 2923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.